Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertension

被引:55
作者
Kruzliak, Peter [1 ,2 ]
Kovacova, Gabriela [3 ]
Pechanova, Olga [1 ]
机构
[1] Slovak Acad Sci, Inst Normal & Pathol Physiol, Ctr Excellence Regulatory Role Nitr Oxide Civiliz, Bratislava 81371, Slovakia
[2] Masaryk Univ, St Annes Fac Hosp, Int Clin Res Ctr, Dept Cardiovasc Dis, Brno, Czech Republic
[3] Univ Hosp, Dept Internal Med, Bratislava, Slovakia
关键词
Angiogenesis; Vascular endothelial growth factor; Anti-angiogenic therapy; Nitric oxide donors; Cell proliferation; ENDOTHELIAL GROWTH-FACTOR; RENAL-CELL CARCINOMA; METASTATIC COLORECTAL-CANCER; PROTEIN-KINASE-C; TARGETED THERAPY; NO SYNTHESIS; VEGF; BEVACIZUMAB; MECHANISMS; SUNITINIB;
D O I
10.1007/s10456-012-9327-4
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Angiogenesis is critical to tumor growth as well as to metastases. This process is tightly regulated by pro- and anti-angiogenic growth factors and their receptors. Some of these factors are highly specific for the endothelium-e.g., vascular endothelial growth factor (VEGF). A variety of drugs that target VEGF or its receptors have been developed for the treatment of different tumor types and a number of new agents is expected to be introduced within the coming years. However, clinical experience has revealed that inhibition of VEGF induces several side effects including hypertension and renal and cardiac toxicity. Angiogenesis-inhibitor-induced hypertension represents "crux medicorum" as it is often pharmacoresistant to antihypertensive therapy. We consider two most important pathomechanisms in the development of hypertension induced by angiogenesis inhibitors. The first represents direct inhibition of NO production leading to reduced vasodilatation and the second consists in increased proliferation of vascular medial cells mediated by NO deficiency and is resulting in fixation of hypertension. Based on the results of experimental and clinical studies as well as on our clinical experience, we assume that NO donors could be successfully used not only for the treatment of developed angiogenesis-inhibitor-induced hypertension but also for preventive effects. We thoroughly documented three clinical cases of cancer patients with resistant hypertension who on receiving NO donor treatment achieved target blood pressure level and a good clinical status.
引用
收藏
页码:289 / 295
页数:7
相关论文
共 47 条
  • [1] Molecular basis of hypertension side effects induced by sunitinib
    Aparicio-Gallego, Guadalupe
    Afonso-Afonso, Francisco J.
    Leon-Mateos, Luis
    Firvida-Perez, Jose L.
    Vazquez-Estevez, Sergio
    Lazaro-Quintela, Martin
    Ramos-Vazquez, Manuel
    Fernandez-Calvo, Ovidio
    Campos-Balea, Begona
    Anton-Aparicio, Luis M.
    [J]. ANTI-CANCER DRUGS, 2011, 22 (01) : 1 - 8
  • [2] Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity
    Azad, Nilofer S.
    Posadas, Edwin M.
    Kwitkowski, Virginia E.
    Steinberg, Seth M.
    Jain, Lokesh
    Annunziata, Christina M.
    Minasian, Lori
    Sarosy, Gisele
    Kotz, Herbert L.
    Premkumar, Ahalya
    Cao, Liang
    McNally, Deborah
    Chow, Catherine
    Chen, Helen X.
    Wright, John J.
    Kohn, Elise C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (22) : 3709 - 3714
  • [3] Home blood-pressure monitoring in patients receiving sunitinib
    Azizi, Michel
    Chedid, Antoine
    Oudard, Stephane
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (01) : 95 - 97
  • [4] Babal P, 1997, HISTOL HISTOPATHOL, V12, P623
  • [5] Current Insights on the Biology and Clinical Aspects of VEGF Regulation
    Birk, Daniel M.
    Barbato, Joel
    Mureebe, Leila
    Chaer, Rabih A.
    [J]. VASCULAR AND ENDOVASCULAR SURGERY, 2008, 42 (06) : 517 - 530
  • [6] Anti-angiogenic therapy in the treatment of advanced renal cell cancer
    Board, Ruth E.
    Thistlethwaite, Fiona C.
    Hawkins, Robert E.
    [J]. CANCER TREATMENT REVIEWS, 2007, 33 (01) : 1 - 8
  • [7] Mechanisms of angiogenesis and arteriogenesis
    Carmeliet, P
    [J]. NATURE MEDICINE, 2000, 6 (04) : 389 - 395
  • [8] Adverse effects of anticancer agents that target the VEGF pathway
    Chen, Helen X.
    Cleck, Jessica N.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2009, 6 (08) : 465 - 477
  • [9] Hypertension and targeted therapy Part 1: Bevacizumab
    Chowdhury, Simon
    Spicer, James F.
    Harper, Peter G.
    [J]. TARGETED ONCOLOGY, 2006, 1 (02) : 104 - 108
  • [10] Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
    Chu, Tammy F.
    Rupnick, Maria A.
    Kerkela, Risto
    Dallabrida, Susan M.
    Zurakowski, David
    Nguyen, Lisa
    Woulfe, Kathleen
    Pravda, Elke
    Cassiola, Flavia
    Desai, Jayesh
    George, Suzanne
    Morgan, Jeffrey A.
    Harris, David M.
    Ismail, Nesreen S.
    Chen, Jey-Hsin
    Schoen, Frederick J.
    Van den Abbeele, Annick D.
    Demetri, George D.
    Force, Thomas
    Chen, Ming Hui
    [J]. LANCET, 2007, 370 (9604) : 2011 - 2019